Name : ASLI
Surname / Last Name : VATAN
Title :Assistant Professor of Infectious Diseases
Language Proficiency : English
Education:
● İstanbul University Cerrahpaşa Faculty of Medicine (Medicine)
● İstanbul University Cerrahpaşa Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology (Specialization)
Work Experience (Organization Name, Start and End Dates of Employment) :
● Sakarya University Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Assistant Professor (2022 - ....)
● Sakarya University Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Specialist Physician (2018 - 2022)
● Hendek State Hospital, Department of Infectious Diseases and Clinical Microbiology, Specialist Physician (2017 - 2018)
● İstanbul University Cerrahpaşa Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Research Assistant (2010 - 2016)
Areas of Expertise:
● ...
● ...
● ...
Certifications:
● ICH Good Clınıcal Practıce E6(R2) (2024)
Specialized Services and Scientific Publications :
Clinical Studies Participated in as a Researcher
● Pfizer C4671002 A Phase 2/3, Randomized, Double-Blind, Two-Arm, Interventional Study to Evaluate the Efficacy and Safety of Orally Administered PF-07321332/Ritonavir Compared with Placebo in Non-Hospitalized Symptomatic Adult Participants with COVID-19 at Low Risk of Progression to Severe Disease. (2021-2022)
● PfizerC4671005A Phase 2/3, Randomized, Double-Blind, Two-Arm, Interventional Study to Evaluate the Efficacy and Safety of Orally Administered PF-07321332/Ritonavir Compared with Placebo in Non-Hospitalized Symptomatic Adult Participants with COVID-19 at High Risk of Progression to Severe Disease. (2021-2022)
● PfizerC4671006A Phase 2/3, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Orally Administered PF-07321332/Ritonavir Given as a Two-Drug Regimen for the Prevention of Symptomatic SARS-CoV-2 Infection in Adult Household Contacts of Individuals with Symptomatic COVID-19. (2021-2022)
● C4591001 A Phase 1/2/3, Randomized, Placebo-Controlled, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals. (2020-2022)
Publication List
1:Vatan A, Güçlü E, Öğütlü A, Kibar FA, Karabay O. Knowledge and attitudes towards COVID-19 among emergency medical service workers. Rev Assoc Med Bras (1992). 2020 Nov;66(11):1553-1559. doi: 10.1590/1806-9282.66.11.1553. PMID: 33295409.
2: Utku AÇ, Budak G, Karabay O, Okan HD, Vatan A. Main symptoms in patients presenting in the COVID-19 period. Scottish Medical Journal 2020 Aug, 65(4) 127–132.
3:Vatan A, Saltoglu N, Yemisen M, Balkan İ, Demiray T, Mete B, Tabak FAssociation between biofilm and multi/extensive drug resistance in diabetic foot infection. Int J Clin Pract 2018 Mar;72,3.
4: Sohrabi P, Habip Z, Sarıbas S, Vatan A, Dinç O, Altun Y. Neopterin and soluble CD14 (sCD14) levels as immunoactivation markers in aHBC-only cases. Future Virology 2017; 12, 8.
5: Saltoglu N, Yemisen M, Ergonul O, Kadanali A, Karagoz G, Batirel A, Ak O, Eraksoy H, Cagatay A, Vatan A, et al; KLIMIK Turkish Society, Diabetic Foot Study Group. Predictors for limb loss among patient with diabetic foot infections: an observational retrospective multicentric study in Turkey. Clin Microbiol Infect. 2015 Jul;21(7):659-64. doi: 10.1016/j.cmi.2015.03.018. Epub 2015 Apr 8. PMID: 25861844.
6: Ozaras R, Karaismailoglu B, Vatan A, Hasiloglu Z, Sahin S, Oz B. Cerebral toxoplasmosis. QJM: An International Journal of Medicine, 2016 Jun; 109(7): 491–492.
7: Vatan A, Saltoglu N. Biofilm and Diabetic Foot Infections Klimik Dergisi 2017; 30: 101-107.
8:Oner Vatan A, Mete B, Yemisen M, Kaya A, Kantarcı F, Saltoglı N. A case of Fasciola hepatica mimicking sepsis without eosinophilia Turkiye Parazitol Derg. 2014 Jun;38(2):131- 136.
9: Acar BA, Acar T, Vatan MB, Aras YG, Ulaş SB, Eryılmaz HA, Dalkılıç Ş, Zafer AP, Turhan O, Vatan A, Varım P, Kaya T. Predictive value of systemic immune-inflammation index for cerebral reperfusion and clinical outcomes in patients with acute ischemic stroke undergoing endovascular treatment. Eur Rev Med Pharmacol Sci. 2022 Aug;26(16):5718-5728.
10: Surme S, Saltoglu N, Kurt AF, Karaali R, Balkan II, Baghaki S, Caglar B, Ozdemir M, Vatan A, Togluk-Yigitoglu E, Budak B, Arapi B, Seker A, Can G, Gonen MS, Cetinkale O; Cerrahpasa Medical Faculty Diabetic Foot Infections Study Group (DAİÇG). Changing Bacterial Etiology and Antimicrobial Resistance Profiles as Prognostic Determinants of Diabetic Foot Infections: A Ten-Year Retrospective Cohort Study. Surg Infect (Larchmt). 2022 Sep;23(7):667-674.
11: Genc AC, Karabay O, Güçlü E, Çalıca Utku A, Vatan A, Tuna N, Budak G, Şimşek A, Uzun C, Alan S, Okan HD, Genc FT, Öğütlü A. New Prognostic Parameter of West Nile Virus: Platelet Distribution Width. Vector Borne Zoonotic Dis. 2023 Oct 12.
12: O Karabay, Aç Utku, A Vatan, G Budak, Guclu E. Covıd-19 Tanılı Hastalarda 30 Gün Sonraki Semptomların İrdelenmesi. Flora İnfeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi. 2021;26(3):419-425.
13. Kaya, Tezcan, et al. "C‐reactive protein/albumin ratio as a novel predictor for nutritional status of geriatric patients." Brain and Behavior 14.9 (2024): e70017.
14. Budak, Gokcen Gurkok, et al. "Concordance between homeostatic model assessment and triglyceride glucose index in assessing insulin resistance among HIV-infected patients." Saudi Medical Journal 46.2 (2025): 157.
15. Karabay O, Vatan A, Ucar A, Yilmaz I, Balta NC, Kanturk A, Dumlu R, Cag Y, Caskurlu H, Şik MT, Otman ZA, Balci U, Senbayrak S, Akhan S, Deniz MT, Yekenkurul D, Ince N, Tunca B, Cakirca TD, Bastug A, Erkorkmaz U, Guclu E. Long-term metabolic and safety profiles of tenofovir alafenamide and tenofovir disoproxil fumarate in ART-naive people living with HIV: a multicenter retrospective study using a mixed-effects model. BMC Pharmacol Toxicol. 2025 Oct 14;26(1):164. doi: 10.1186/s40360-025-01003-0. PMID: 41088309; PMCID: PMC12523089.
16. Vatan A, Emre S, Budak GG, Güçlü E, Öğütlü A, Karabay O. Systemic inflammation response index predicts short-term mortality in intensive care unit patients with bacterial bloodstream infections. BMC Infect Dis. 2026 Jan 17. doi: 10.1186/s12879-026-12552-y. Epub ahead of print. PMID: 41547715.